Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

126.64 -2.26 (-1.75%)
Streaming Delayed Price Updated: 2:40 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,515,646
Open 129.00
Bid (Size) 126.59 (2)
Ask (Size) 126.71 (2)
Prev. Close 128.90
Today's Range 124.75 - 129.15
52wk Range 115.03 - 217.25
Shares Outstanding 384,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Moderna Unusual Options Activity For June 06
 
Via Benzinga
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
Benzinga 
Via Benzinga

Performance

YTD
-29.25%
-29.25%
1 Month
-3.88%
-3.88%
3 Month
-12.07%
-12.07%
6 Month
-28.02%
-28.02%
1 Year
-9.54%
-9.54%

More News

Read More
Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants
Via Benzinga
3 Biotech Stocks to Sell in June Before They Crash and Burn
Via InvestorPlace
Looking At Moderna's Recent Unusual Options Activity
Via Benzinga
Moderna to Present at Upcoming Conferences in June 2023
Via ACCESSWIRE
2 Healthcare AI Stocks to Buy on the Dip
Via The Motley Fool
Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%
Via Benzinga
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
Via ACCESSWIRE
Growth Stocks Look Primed for a Rally. Is It Time to Jump Back In?
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
Looking At Moderna's Recent Unusual Options Activity
Via Benzinga
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
Via ACCESSWIRE
Better Healthcare AI Stock: Moderna vs. Doximity
Via The Motley Fool
COVID Concerns Are Rising in China Again: Will This Send Moderna's Stock Soaring?
Via The Motley Fool
3 Innovative Growth Stocks to Buy for Next-Gen Profits
Via InvestorPlace
Do You Really Want AI To Pick Your Stocks?
Via Talk Markets
If You Invested $2,500 in Moderna in 2019, This Is How Much You Would Have Today
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Top Stock Tips for June 2023
Via InvestorPlace
7 Stocks That Even Company Insiders are Selling
Via InvestorPlace
GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results
Via Benzinga
As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.